ADMA Biologics (ADMA) vs Immunome (IMNM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Immunome (IMNM) has outperformed ADMA Biologics (ADMA) over the past year, gaining 37.8% versus a loss of 29.3%. Over five years, ADMA leads with a +839.1% price change compared with +9.7% for IMNM. ADMA Biologics is the larger company by market cap ($2.31 billion vs $2.28 billion), about 1.0 times the size.
ADMA Biologics converts more of its revenue into profit, with a net margin of 28.8% versus -3060.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADMA | IMNM |
|---|---|---|
| Share price | $10.33 | $19.31 |
| Market cap | $2.31B | $2.28B |
| 1-day change | +1.87% | +1.13% |
| YTD return | -43.37% | -10.10% |
| 1-year return | -29.34% | +37.83% |
| 5-year return | +839.09% | +9.65% |
| P/E ratio (TTM) | 14.76 | — |
| Forward P/E | 10.95 | — |
| EPS (TTM) | $0.70 | $-2.55 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $510.17M | $6.94M |
| Revenue growth (YoY) | +19.63% | -23.23% |
| Net income (latest FY) | $146.93M | $-212.39M |
| Gross margin | 57.39% | — |
| Operating margin | 37.53% | -3228.83% |
| Net margin | 28.80% | -3059.99% |
| 52-week high | $20.46 | $30.06 |
| 52-week low | $7.21 | $13.49 |
| Distance from 52-week high | -49.51% | -35.76% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +64.57% | +82.29% |
| Average volume | 2.63M | 1.20M |
| Shares outstanding | 223.98M | 118.00M |
| Employees | 640 | 247 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMNM has outperformed ADMA by 67.2 percentage points over the past year.
- ADMA Biologics is more profitable, keeping 28.8 cents of every revenue dollar as net income versus -3060.0 cents for Immunome.
- ADMA Biologics grew revenue faster in its latest fiscal year (+19.63% vs -23.23%).
- The two companies sit in different sectors: ADMA Biologics in Health Care and Immunome in Healthcare.
About ADMA Biologics
ADMA stock →ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 640 employees
About Immunome
IMNM stock →Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.
Healthcare · Biotechnology · 247 employees
ADMA vs IMNM FAQ
Which is bigger, ADMA Biologics or Immunome?
ADMA Biologics (ADMA) is larger, with a market capitalization of $2.31B compared with $2.28B for Immunome (IMNM).
Which stock has performed better over the past year, ADMA or IMNM?
IMNM returned +37.83% over the past 12 months, compared with -29.34% for ADMA (price return, excluding dividends). Past performance does not predict future results.
Are ADMA Biologics and Immunome in the same industry?
No. ADMA Biologics is in the Health Care sector, while Immunome is in Healthcare.